{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T03:12:08Z","timestamp":1792293128105,"version":"4.4.0"},"reference-count":66,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2017]]},"DOI":"10.3960\/jslrt.17008","type":"journal-article","created":{"date-parts":[[2017,6,7]],"date-time":"2017-06-07T22:06:04Z","timestamp":1496873164000},"page":"87-97","source":"Crossref","is-referenced-by-count":32,"title":["Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma"],"prefix":"10.3960","volume":"57","author":[{"given":"Hiroo","family":"Katsuya","sequence":"first","affiliation":[{"name":"Center for AIDS Research, Kumamoto University"},{"name":"Department of Medicine, Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishitsuka","sequence":"additional","affiliation":[{"name":"Division of Hematology and Immunology, Center for Chronic Viral Diseases Graduate School of Medical and Dental Sciences, Kagoshima University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 de The G, Bomford R: An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 9:381-6, 1993","DOI":"10.1089\/aid.1993.9.381"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Gessain A, Cassar O: Epidemiological Aspects and World Distribution of HTLV-1 Infection. Front Microbiol 3:388, 2012","DOI":"10.3389\/fmicb.2012.00388"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Proietti FA, Carneiro-Proietti AB, Catalan-Soares BC, Murphy EL: Global epidemiology of HTLV-I infection and associated diseases. Oncogene 24:6058-68, 2005","DOI":"10.1038\/sj.onc.1208968"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Iwanaga M, Watanabe T, Yamaguchi K: Adult T-cell leukemia: a review of epidemiological evidence. Front Microbiol 3:322, 2012","DOI":"10.3389\/fmicb.2012.00322"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 79:428-37, 1991","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"6","unstructured":"6 Shimoyama M: Chemotherapy of ATL, in Takatsuki K (ed): Adult T-Cell Leukemia. Oxford, United Kingdom, Oxford University Press, 1994, pp 221-237"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, <i>et al<\/i>: Treatment and survival among 1594 patients with ATL. Blood 126:2570-7, 2015","DOI":"10.1182\/blood-2015-03-632489"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, <i>et al<\/i>: Long-term study of indolent adult T-cell leukemia-lymphoma. Blood 115:4337-43, 2010","DOI":"10.1182\/blood-2009-09-242347"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Katsuya H, Yamanaka T, Ishitsuka K, Utsunomiya A, Sasaki H, Hanada S, <i>et al<\/i>: Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol 30:1635-40, 2012","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Katsuya H, Shimokawa M, Ishitsuka K, Kawai K, Amano M, Utsunomiya A, <i>et al<\/i>: Prognostic index for chronic and smoldering types adult T-cell leukemia\/lymphoma. Journal of Clinical Oncology 33:8522-8522, 2015 (abstract)","DOI":"10.1200\/jco.2015.33.15_suppl.8522"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, <i>et al<\/i>: A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 113:375-82, 2001","DOI":"10.1046\/j.1365-2141.2001.02737.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, <i>et al<\/i>: VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol 25:5458-64, 2007","DOI":"10.1200\/JCO.2007.11.9958"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, <i>et al<\/i>: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol 30:837-42, 2012","DOI":"10.1200\/JCO.2011.37.3472"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, <i>et al<\/i>: Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. Br J Haematol 169:672-82, 2015","DOI":"10.1111\/bjh.13338"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, <i>et al<\/i>: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol 28:4177-83, 2010","DOI":"10.1200\/JCO.2010.28.0669"},{"key":"16","unstructured":"16 Shimoyama M IM, Yunoki K, Oota K, Ogawa M: Final results of cooperative study of VEPA [vincristine, cyclophosphamide (endoxan), prednisolone and adriamycin] therapy in advanced adultnon-Hodgkin\u2019s lymphoma: relation between T- or B-cell phenotype and response. Jpn J Clin Oncol 12, 1982"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Shimoyama M, Ota K, Kikuchi M, Yunoki K, Konda S, Takatsuki K, <i>et al<\/i>: Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin\u2019s lymphoma treated with VEPA or VEPA-M. J Clin Oncol 6:128-41, 1988","DOI":"10.1200\/JCO.1988.6.1.128"},{"key":"18","unstructured":"18 Tobinai K SM, Minato K, Shirakawa S, Kobayashi T, Hotta T, <i>et al<\/i>.: Japan Clinical Oncology Group phase II trial of second-generation \u201bLSG4 protocol\u2019 in aggressive T- and B-lymphoma: a new predictive model FOR T-and B-lymphoma. Proc Am Soc Clin Oncol, 1994 (abstract)"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Tsukasaki K, Tobinai K, Shimoyama M, Kozuru M, Uike N, Yamada Y, <i>et al<\/i>: Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109). Int J Hematol 77:164-70, 2003","DOI":"10.1007\/BF02983215"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Yoshie O, Fujisawa R, Nakayama T, Harasawa H, Tago H, Izawa D, <i>et al<\/i>: Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. Blood 99:1505-11, 2002","DOI":"10.1182\/blood.V99.5.1505"},{"key":"21","unstructured":"21 Ishida T, Utsunomiya A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, <i>et al<\/i>: Clinical significance of CCR4 expression in adult T-cell leukemia\/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-34, 2003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Phillips A, Fields P, Hermine O, Ramos JC, Beltran BE, Pereira J, <i>et al<\/i>: A Prospective, Multicenter, Randomized Study of Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Investigator\u2019s Choice in the Treatment of Patients with Relapsed\/Refractory Adult T-Cell Leukemia -Lymphoma: Overall Response Rate, Progression-Free Survival, and Overall Survival. Blood 128:4159-4159, 2016 (abstract)","DOI":"10.1200\/JCO.2016.34.15_suppl.7501"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Iyama S, Sato T, Ohnishi H, Kanisawa Y, Ohta S, Kondo T, <i>et al<\/i>: A Multicenter Retrospective Study of Mogamulizumab Efficacy in Adult T-Cell Leukemia\/Lymphoma. Clin Lymphoma Myeloma Leuk 17:23-30.e2, 2017","DOI":"10.1016\/j.clml.2016.09.009"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Fuji S, Inoue Y, Utsunomiya A, Moriuchi Y, Uchimaru K, Choi I, <i>et al<\/i>: Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia\/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. J Clin Oncol 34:3426-33, 2016","DOI":"10.1200\/JCO.2016.67.8250"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Utsunomiya A, Miyazaki Y, Takatsuka Y, Hanada S, Uozumi K, Yashiki S, <i>et al<\/i>: Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 27:15-20, 2001","DOI":"10.1038\/sj.bmt.1702731"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Kami M, Hamaki T, Miyakoshi S, Murashige N, Kanda Y, Tanosaki R, <i>et al<\/i>: Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia\/lymphoma. Br J Haematol 120:304-9, 2003","DOI":"10.1046\/j.1365-2141.2003.04054.x"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, <i>et al<\/i>: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma. Leukemia 19:829-34, 2005","DOI":"10.1038\/sj.leu.2403682"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Okamura J, Utsunomiya A, Tanosaki R, Uike N, Sonoda S, Kannagi M, <i>et al<\/i>: Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia\/lymphoma. Blood 105:4143-5, 2005","DOI":"10.1182\/blood-2004-11-4193"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, <i>et al<\/i>: Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia\/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant 13:90-9, 2007","DOI":"10.1016\/j.bbmt.2006.09.002"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, <i>et al<\/i>: A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia\/lymphoma (ATL): clinical impact of graft-versus-leukemia\/lymphoma effect. Biol Blood Marrow Transplant 14:817-23, 2008","DOI":"10.1016\/j.bbmt.2008.04.014"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Tanosaki R, Uike N, Utsunomiya A, Saburi Y, Masuda M, Tomonaga M, <i>et al<\/i>: Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia\/lymphoma: impact of antithymocyte globulin on clinical outcome. Biol Blood Marrow Transplant 14:702-8, 2008","DOI":"10.1016\/j.bbmt.2008.03.010"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Choi I, Tanosaki R, Uike N, Utsunomiya A, Tomonaga M, Harada M, <i>et al<\/i>: Long-term outcomes after hematopoietic SCT for adult T-cell leukemia\/lymphoma: results of prospective trials. Bone Marrow Transplant 46:116-8, 2011","DOI":"10.1038\/bmt.2010.92"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Nakamura T, Oku E, Nomura K, Morishige S, Takata Y, Seki R, <i>et al<\/i>: Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute. Int J Hematol 96:657-63, 2012","DOI":"10.1007\/s12185-012-1177-8"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Fukushima T, Itonaga H, Moriuchi Y, Yoshida S, Taguchi J, Imaizumi Y, <i>et al<\/i>: Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia\/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol 97:485-90, 2013","DOI":"10.1007\/s12185-013-1307-y"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Bazarbachi A, Cwynarski K, Boumendil A, Finel H, Fields P, Raj K, <i>et al<\/i>: Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transplant 49:1266-8, 2014","DOI":"10.1038\/bmt.2014.143"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Kato K, Choi I, Wake A, Uike N, Taniguchi S, Moriuchi Y, <i>et al<\/i>: Treatment of patients with adult T cell leukemia\/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey. Biol Blood Marrow Transplant 20:1968-74, 2014","DOI":"10.1016\/j.bbmt.2014.08.012"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Ishida T, Hishizawa M, Kato K, Tanosaki R, Fukuda T, Taniguchi S, <i>et al<\/i>: Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study. Blood 120:1734-41, 2012","DOI":"10.1182\/blood-2012-03-414490"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Kanda J, Hishizawa M, Utsunomiya A, Taniguchi S, Eto T, Moriuchi Y, <i>et al<\/i>: Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood 119:2141-8, 2012","DOI":"10.1182\/blood-2011-07-368233"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Shigematsu A, Kobayashi N, Yasui H, Shindo M, Kakinoki Y, Koda K, <i>et al<\/i>: High level of serum soluble interleukin-2 receptor at transplantation predicts poor outcome of allogeneic stem cell transplantation for adult T cell leukemia. Biol Blood Marrow Transplant 20:801-5, 2014","DOI":"10.1016\/j.bbmt.2014.02.014"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Kawada H, Yoshimitsu M, Nakamura D, Arai A, Hayashida M, Kamada Y, <i>et al<\/i>: A retrospective analysis of treatment outcomes in adult T cell leukemia\/lymphoma patients with aggressive disease treated with or without allogeneic stem cell transplantation: A single-center experience. Biol Blood Marrow Transplant 21:696-700, 2015","DOI":"10.1016\/j.bbmt.2014.12.020"},{"key":"41","unstructured":"41 Gill PS, Harrington W, Jr., Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, <i>et al<\/i>: Treatment of adult T-cell leukemialymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 332:1744-8, 1995"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, <i>et al<\/i>: Brief report: treatment of adult T-cell leukemialymphoma with zidovudine and interferon alfa. N Engl J Med 332:1749-51, 1995","DOI":"10.1056\/NEJM199506293322604"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 White JD, Wharfe G, Stewart DM, Maher VE, Eicher D, Herring B, <i>et al<\/i>: The combination of zidovudine and interferon alpha-2B in the treatment of adult T-cell leukemia\/lymphoma. Leuk Lymphoma 40:287-94, 2001","DOI":"10.3109\/10428190109057927"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, <i>et al<\/i>: Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 113:779-84, 2001","DOI":"10.1046\/j.1365-2141.2001.02794.x"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Hodson A, Crichton S, Montoto S, Mir N, Matutes E, Cwynarski K, <i>et al<\/i>: Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma. J Clin Oncol 29:4696-701, 2011","DOI":"10.1200\/JCO.2011.35.5578"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, <i>et al<\/i>: Identification of a primary target of thalidomide teratogenicity. Science 327:1345-50, 2010","DOI":"10.1126\/science.1177319"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47 Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, <i>et al<\/i>: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia 26:2326-35, 2012","DOI":"10.1038\/leu.2012.119"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48 Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, <i>et al<\/i>: A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer 49:2869-76, 2013","DOI":"10.1016\/j.ejca.2013.04.029"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49 Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, <i>et al<\/i>: Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer 121:716-23, 2015","DOI":"10.1002\/cncr.29103"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50 Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, <i>et al<\/i>: Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia\/Lymphoma: ATLL-002. J Clin Oncol, 2016","DOI":"10.1200\/JCO.2016.67.7732"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51 Minucci S, Pelicci PG: Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38-51, 2006","DOI":"10.1038\/nrc1779"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52 Tsukasaki K, Tobinai K: Human T-cell lymphotropic virus type I-associated adult T-cell leukemia-lymphoma: new directions in clinical research. Clin Cancer Res 20:5217-25, 2014","DOI":"10.1158\/1078-0432.CCR-14-0572"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53 Onizuka M, Ando K, Yoshimitsu M, Ishida T, Yoshida S, Choi I, <i>et al<\/i>: Oral HDAC Inhibitor HBI8000 in Japanese Patients with Non-Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results. Blood 128:1827-1827, 2016 (abstract)","DOI":"10.1182\/blood.V128.22.1827.1827"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54 Rao SP, Sancho J, Campos-Rivera J, Boutin PM, Severy PB, Weeden T, <i>et al<\/i>: Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7:e39416, 2012","DOI":"10.1371\/journal.pone.0039416"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55 Sharma K, Janik JE, O\u2019Mahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, <i>et al<\/i>: Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia\/lymphoma. Clin Cancer Res 23:35-42, 2017","DOI":"10.1158\/1078-0432.CCR-16-1022"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56 Wen B, Z hang M, Di lillo D, Ra vetch JV, Waldmann TA: Interleukin-15 enhances rituximab-dependent cytotoxicity ex vivo and <i>in vivo<\/i> against a mouse lymphoma expressing human CD20. Cancer Research 75:1332-1332, 2015 (abstract)","DOI":"10.1158\/1538-7445.AM2015-1332"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57 Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, <i>et al<\/i>: Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol 30:2183-9, 2012","DOI":"10.1200\/JCO.2011.38.0410"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58 Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, <i>et al<\/i>: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 30:2190-6, 2012","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59 Horwitz SM, Advani RH, Bartlett NL, Jacobsen ED, Sharman JP, O\u2019Connor OA, <i>et al<\/i>: Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. Blood 123:3095-100, 2014","DOI":"10.1182\/blood-2013-12-542142"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60 Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, <i>et al<\/i>: Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. Blood 128:2993-2993, 2016 (abstract)","DOI":"10.1182\/blood.V128.22.2993.2993"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61 Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, <i>et al<\/i>: Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32:1020-30, 2014","DOI":"10.1200\/JCO.2013.53.0105"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62 Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, <i>et al<\/i>: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-54, 2012","DOI":"10.1056\/NEJMoa1200690"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63 Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, <i>et al<\/i>: PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372:311-9, 2015","DOI":"10.1056\/NEJMoa1411087"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64 Miyoshi H, Kiyasu J, Kato T, Yoshida N, Shimono J, Yokoyama S, <i>et al<\/i>: PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma. Blood 128:1374-1381, 2016","DOI":"10.1182\/blood-2016-02-698936"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65 Sasaki D, Imaizumi Y, Hasegawa H, Osaka A, Tsukasaki K, Choi YL, <i>et al<\/i>: Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia\/lymphoma as a tar get for epigenetic therapy. Haematologica 96:712-9, 2011","DOI":"10.3324\/haematol.2010.028605"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66 Fujikawa D, Nakagawa S, Hori M, Kurokawa N, Soejima A, Nakano K, <i>et al<\/i>: Polycomb-dependent epigenetic landscape in adult T-cell leukemia. Blood 127:1790-1802, 2016","DOI":"10.1182\/blood-2015-08-662593"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17008\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T18:33:06Z","timestamp":1602268386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/57\/3\/57_17008\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.17008","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}